In her fascinating book entitled Advancing Healthcare Through Personalized Medicine, Priya Hays brings the exciting world of personalized medicine to life. She explores how precision medicine and immunotherapies are revolutionizing care for cancer patients, making treatments more effective and tailored to individual genetic profiles. In particular, Hays focuses on cancers that have poor survival rates, for which innovative treatments are urgently required. Read More
For metastatic breast cancer, which typically has a poor prognosis, a new drug called Herceptin has been used extensively in the past two decades. Herceptin targets HER2-positive breast cancer, where the tumor cells express a lot of HER2 proteins on their surfaces, allowing them to multiply rapidly. In clinical trials, Herceptin slowed down or stopped cancer growth, allowing patients to live longer.
Other immunotherapy drugs such as pembrolizumab help the body’s immune system to effectively target and kill cancer cells. When combined with chemotherapy, pembrolizumab is particularly beneficial for patients with triple-negative breast cancer, which is usually very difficult to treat.
For lung cancer, personalized treatments are also making a significant impact. For instance, alectinib is a precision drug that improves outcomes for patients with ALK-positive lung cancer, which typically has very low survival rates.
Immunotherapy is also making waves in lung cancer treatment. In particular, nivolumab and pembrolizumab are particularly effective in patients whose cancer cells have high levels of proteins called PD1 and PDL1 on their surfaces. These antibody-based drugs help the immune system to block the growth and spread of cancer cells, greatly enhancing patient outcomes.
Melanoma, a serious form of skin cancer, has seen advancements in these areas too. For patients with a mutation in the BRAF gene that causes normal cells to become cancerous, targeted drugs called vemurafenib and dabrafenib are very effective. Immunotherapy is also a game-changer for melanoma, significantly improving the survival of patients with advanced disease.
Prostate cancer treatments are evolving too. A precision drug called olaparib is used in first-line settings with chemotherapy for prostate cancer patients with mutations in BRCA1, BRCA2, or ATM genes. Additionally, this targeted therapy is highly effective for ovarian cancer – which often has a poor survival rate.
In her book, Hays vividly illustrates how these personalized approaches are transforming cancer treatment. As targeted therapies and immunotherapies continue to transform how we treat cancer, patients are gaining new hope for better outcomes and longer lives. Hays highlights the importance of ongoing research and the continuous development of these treatments to make them even more effective for everyone.
